# IMmune Proteomics to Predict neoAdjuvant Chemotherapy and immunoTherapy Response in Gastric Cancer

> **NCT06662110** · — · RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 206 (estimated)

## Conditions studied

- Gastric Cancer, Gastroesophageal Junction Cancer

## Interventions

- **DIAGNOSTIC_TEST:** PSRscore

## Key facts

- **NCT ID:** NCT06662110
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2026-06-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 206 (ESTIMATED)
- **Last updated:** 2024-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06662110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06662110, "IMmune Proteomics to Predict neoAdjuvant Chemotherapy and immunoTherapy Response in Gastric Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06662110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*